ClinicalTrials.gg
RecruitingNCT07771010EMPOWERUpdated Aug 18, 2026

The Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvascular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellitus

A Phase 4 interventional study of Empagliflozin (Jardiance®) and Metformin in Diabetes Type 2, sponsored by University Medical Centre Ljubljana. Recruiting at 1 site in Slovenia. Open to male participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-18.

Sponsored by University Medical Centre Ljubljana · Phase 4, Interventional, and Basic science

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Apr 2026, registered Jul 2026).
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Planned enrollment
82nd of 130
54 · median 79
Started
2026
with 7 others
Phase 4
50 of 130
11 open now
Primary completion
2027-12
later than 16 of 18 live
Registered
128th of 130
by date

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 82nd largest by planned enrollment, is one of 8 that started in 2026, is one of 50 in phase 4, reaches primary completion later than 16 of the 18 other live ones, and was the 128th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

12 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

The purpose of the study is to compare the effect of empagliflozin, metformin, and the combination of both on the oxidative capacity of skeletal muscle and its microvascular reactivity in individuals with newly diagnosed type 2 diabetes. As the primary outcome, the investigators selected the change in skeletal muscle oxidative capacity and posed the following scientific question: Does empagliflozin significantly improve the oxidative capacity of skeletal muscle? The study will enroll 54 individuals with type 2 diabetes in a prospective, randomized, interventional, open-label study. Participants will be randomized into 3 equally sized groups: 1) a group receiving empagliflozin; 2) a group receiving metformin; and 3) a group receiving a combination of both drugs (empagliflozin and metformin). The investigators will analyze the clinical variables of the subjects, near-infrared spectroscopy (NIRS) measurements over the flexor digitorum superficialis muscle of the non-dominant arm at rest, after submaximal muscular work, and during transient brachial artery occlusion at specified time intervals (14 days, 1 month, 3 months, 6 months), as well as body composition, physical performance, and glycemic control following the pharmacological intervention.

Read the detailed description

Type 2 diabetes mellitus is associated with impaired skeletal muscle mitochondrial oxidative capacity and microvascular dysfunction, both of which contribute to reduced exercise tolerance and may precede overt clinical complications. Sodium-glucose co-transporter 2 (SGLT2) inhibitors, such as empagliflozin, have demonstrated cardiovascular and renal benefits in patients with type 2 diabetes through mechanisms that extend beyond glycemic control, including possible effects on mitochondrial function and vascular reactivity. Metformin, the first-line pharmacological treatment for type 2 diabetes, has also been proposed to influence mitochondrial metabolism, though its comparative effect on skeletal muscle oxidative capacity remains incompletely characterized.

This is a prospective, randomized, open-label, interventional study comparing the effects of empagliflozin, metformin, and their combination on skeletal muscle oxidative capacity and microvascular reactivity in individuals with newly diagnosed type 2 diabetes. A total of 54 participants will be randomized in a 1:1:1 ratio (n=18 per group) to: (1) empagliflozin monotherapy, (2) metformin monotherapy, or (3) combination therapy with empagliflozin and metformin.

Study visits and procedures

Baseline visit (Day 0): Participants will be informed of the study procedures and purpose at the diabetes outpatient clinic and invited to participate voluntarily. Those who agree will sign informed consent. Medical records will be reviewed (duration of type 2 diabetes, comorbidities and their treatment, current medications). A clinical examination will be performed, including height, weight, body mass index, blood pressure, and heart rate. Participants will complete a physical activity questionnaire (adapted in part from the International Physical Activity Questionnaire, IPAQ). Maximal handgrip strength will be measured bilaterally using a dynamometer, and a 6-minute walk test will be performed. Blood will be drawn and urine collected for laboratory parameters.

Participants will be instructed to attend each testing visit between 7:00 and 9:00 AM, fasting (12-hour overnight fast), having abstained from caffeine, tobacco, and alcohol, and having avoided moderate-to-vigorous physical activity for at least 24 hours beforehand. To minimize the confounding effect of increased limb use, all measurements will be performed on the non-dominant arm.

Whole-body dual-energy X-ray absorptiometry (DXA) will be used to quantitatively assess body composition. An interstitial glucose monitoring sensor will be applied for the first month of follow-up. Near-infrared spectroscopy (NIRS) measurements will be performed over the flexor digitorum superficialis muscle of the non-dominant forearm at rest, after submaximal muscular work, and during transient brachial artery occlusion, allowing assessment of skeletal muscle oxidative capacity and microvascular reactivity (protocol below). Pharmacological antidiabetic treatment will then be initiated (empagliflozin, metformin, or the combination, per randomization).

Follow-up visits (Day 14, Month 1, Month 3, Month 6): The same protocol will be repeated at each follow-up visit. Body composition will be reassessed at the Month 3 and Month 6 visits.

NIRS sub-protocol Tissue oxygen saturation (StO2) will be measured over the flexor digitorum superficialis muscle using a tissue spectrometer. Three sequential measurements will be obtained: (A) resting StO2 after 5 minutes of rest; (B) StO2 during submaximal handgrip exercise (60% of maximal grip force) interspersed with brief arterial occlusions, used to derive an index of mitochondrial oxidative capacity from the StO2 recovery rate; and (C) StO2 during and following a transient brachial artery occlusion, used to assess microvascular reactivity (peak StO2 and recovery rate after cuff release).

Sample size Sample size was estimated from published values of skeletal muscle oxidative capacity in healthy individuals (2.0 ± 0.3 min-¹), assuming a 20% reduction at baseline in participants with diabetes and a shift toward normal values with empagliflozin treatment (1.7 ± 0.3 min-¹ vs. 2.0 ± 0.3 min-¹), with no effect expected from metformin. With alpha = 0.05 and power = 0.8, at least 16 participants per group are required; 18 per group will be enrolled to allow for dropout.

Statistical analysis Treatment-related changes will be analyzed using one-way repeated measures ANOVA with appropriate post-hoc testing. A P-value less than 0.05 will be considered statistically significant. Statistical analysis will be performed using MedCalc v14 (MedCalc Software bvba).

This study is conducted as a defined sub-study within a larger parent trial evaluating the effects of empagliflozin, metformin, and their combination on skeletal muscle function in individuals with type 2 diabetes (ethics approval by the Republic of Slovenia National Medical Ethics Committee, No. 0120-32/2024-2711-3). This sub-study applies more restrictive inclusion criteria to a homogeneous subgroup of participants (male, aged 40-60 years, BMI 25-35 kg/m²) to minimize confounding related to sex, age, and body composition when assessing the primary outcome of skeletal muscle oxidative capacity.

03

Conditions studied

  • Diabetes Type 2

Keywords

  • type 2 diabetes mellitus
  • Empagliflozin
  • Metformin
  • Skeletal muscle oxidative capacity
  • Near-infrared spectroscopy
  • Microvascular reactivity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male sex
  • Age 18-75 years
  • Newly diagnosed type 2 diabetes mellitus, confirmed no more than 2 years prior to enrollment
  • (BMI) 25-35 kg/m²
  • Currently managed at a diabetes outpatient clinic
  • No known chronic diabetes-related complications
  • No prior antidiabetic pharmacological treatment, with the exception of sulfonylureas

Exclusion criteria

Exclusion Criteria:

  • Other forms of diabetes mellitus (i.e., not type 2)
  • Type 2 diabetes mellitus known for more than 2 years
  • Comorbidities known to independently affect skeletal muscle oxidative capacity, including: spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cystic fibrosis, local joint immobility, or hemiplegia
  • Known mitochondrial disease
  • Heart failure, class II or higher
  • Chronic kidney disease, stage 3 or higher
  • Poorly controlled chronic medical conditions (e.g., arterial hypertension, hypothyroidism)
  • Recurrent urinary tract infections
  • Active currently undergoing oncologic treatment
  • less than 3 months
  • Symptomatic hyperglycemia with fasting plasma glucose above 18 mmol/L, ≥ 10%
  • Unwillingness to provide
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
54 participants (estimated)

Study arms

  • Active comparator
    Empagliflozin

    Participants with newly diagnosed type 2 diabetes will receive empagliflozin monotherapy for 6 months.

    Drug: Empagliflozin (Jardiance®)

  • Active comparator
    Metformin

    Participants with newly diagnosed type 2 diabetes will receive metformin monotherapy for 6 months.

    Drug: Metformin

  • Active comparator
    Empagliflozin + Metformin

    Participants with newly diagnosed type 2 diabetes will receive combination therapy with empagliflozin and metformin for 6 months.

    Combination Product: Synjardy® 12.5mg/1000mg film-coated tablets

Interventions

  • Empagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, empagliflozin will be administered alone (Arm 1) or in combination with metformin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.

  • Metformin is a biguanide antihyperglycemic agent administered orally at a standard therapeutic dose for the treatment of type 2 diabetes mellitus. In this study, metformin will be administered alone (Arm 2) or in combination with empagliflozin (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.

  • Combination productSynjardy® 12.5mg/1000mg film-coated tablets

    Fixed-dose combination product containing empagliflozin and metformin, administered orally at standard therapeutic doses for the treatment of type 2 diabetes mellitus. Used in the combination therapy arm (Arm 3) for 6 months, with skeletal muscle oxidative capacity and microvascular reactivity assessed at baseline and follow-up visits.

06

What researchers measure

Primary outcomes

  1. Change in skeletal muscle mitochondrial oxidative capacity

    Skeletal muscle mitochondrial oxidative capacity will be assessed non-invasively using near-infrared spectroscopy (NIRS) over the flexor digitorum superficialis muscle of the non-dominant forearm. The recovery rate of tissue oxygen saturation (StO2) following submaximal muscular exercise and repeated brief arterial occlusions will be used as an index of mitochondrial oxidative capacity. This outcome will be compared across the three treatment arms to test the hypotheses that empagliflozin increases skeletal muscle oxidative capacity, that metformin does not alter oxidative capacity, and that combination therapy increases oxidative capacity to a lesser degree than empagliflozin monotherapy.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

Secondary outcomes

  1. Change in skeletal muscle microvascular reactivity

    Description: Microvascular reactivity will be assessed using NIRS by measuring peak tissue oxygen saturation (StO2) and StO2 recovery rate following release of a transient brachial artery occlusion. This outcome will be compared across the three treatment arms to test the hypothesis that microvascular reactivity increases to a greater extent in the empagliflozin group compared with the metformin and combination therapy groups.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  2. Change in body fat mass

    Body fat mass will be assessed using whole-body dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline, Month 3, and Month 6

  3. Change in lean body mass

    Lean body mass will be assessed using whole-body dual-energy X-ray absorptiometry (DXA).

    Time frame: Baseline, Month 3, and Month 6

  4. Change in body fat percentage

    Total body fat percentage will be assessed using whole-body DXA.

    Time frame: Baseline, Month 3, and Month 6

  5. Change in appendicular lean mass index

    Appendicular lean mass indexed to height squared will be assessed using whole-body DXA, as a marker of skeletal muscle mass relevant to sarcopenia.

    Time frame: Baseline, Month 3, and Month 6

  6. Change in appendicular lean mass

    Appendicular (limb) lean mass will be assessed using whole-body DXA.

    Time frame: Baseline, Month 3, and Month 6

  7. Change in lean mass index

    Total body lean mass indexed to height squared will be assessed using whole-body DXA.

    Time frame: Baseline, Month 3, and Month 6

  8. Change in glycemic control - fasting plasma glucose

    Fasting plasma glucose will be measured at each study visit.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  9. Change in glycemic control - HbA1c

    Glycated hemoglobin (HbA1c) will be measured at each study visit.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  10. Change in 6-minute walk distance

    Physical performance will be assessed using the 6-minute walk test.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  11. Change in maximal handgrip strength

    Maximal handgrip strength will be assessed bilaterally using a dynamometer.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  12. Change in physical activity level (IPAQ)

    Physical activity level will be assessed using a questionnaire adapted from the International Physical Activity Questionnaire (IPAQ), capturing time spent in vigorous, moderate, walking, and sedentary activity.

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

  13. Change in self-reported physical capacity

    Participants will rate their subjective physical capacity on a scale from 1 (poor capacity) to 10 (able to sustain high-intensity exercise without difficulty).

    Time frame: Baseline, Day 14, Month 1, Month 3, and Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Erickson ML, Ryan TE, Backus D, McCully KK. Endurance neuromuscular electrical stimulation training improves skeletal muscle oxidative capacity in individuals with motor-complete spinal cord injury. Muscle Nerve. 2017 May;55(5):669-675. doi: 10.1002/mus.25393. Epub 2017 Jan 11. PubMed 27576602 ↗
  • Ryan TE, Brophy P, Lin CT, Hickner RC, Neufer PD. Assessment of in vivo skeletal muscle mitochondrial respiratory capacity in humans by near-infrared spectroscopy: a comparison with in situ measurements. J Physiol. 2014 Aug 1;592(15):3231-41. doi: 10.1113/jphysiol.2014.274456. Epub 2014 Jun 20. PubMed 24951618 ↗
  • Ryan TE, Southern WM, Reynolds MA, McCully KK. A cross-validation of near-infrared spectroscopy measurements of skeletal muscle oxidative capacity with phosphorus magnetic resonance spectroscopy. J Appl Physiol (1985). 2013 Dec;115(12):1757-66. doi: 10.1152/japplphysiol.00835.2013. Epub 2013 Oct 17. PubMed 24136110 ↗
  • Brizendine JT, Ryan TE, Larson RD, McCully KK. Skeletal muscle metabolism in endurance athletes with near-infrared spectroscopy. Med Sci Sports Exerc. 2013 May;45(5):869-75. doi: 10.1249/MSS.0b013e31827e0eb6. PubMed 23247709 ↗
  • Hagstromer M, Oja P, Sjostrom M. The International Physical Activity Questionnaire (IPAQ): a study of concurrent and construct validity. Public Health Nutr. 2006 Sep;9(6):755-62. doi: 10.1079/phn2005898. PubMed 16925881 ↗

Individual participant data

Plan to share: Undecided — A decision regarding sharing of individual participant data with external researchers has not yet been made. This will be determined based on institutional data governance requirements, ethics committee guidance, and journal submission requirements at the time of study completion.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2027, 20 months after the start.

Of 320 non-industry phase 4 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 49. This study's planned 20 months is below that.

Counting every sponsor, half of 452 studies reached it within 24 months; a quarter within 13 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Aug 18, 2026
StartActual
Apr 16, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Aug 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07771010
Collaborators
University of Ljubljana, Faculty of Medicine
Responsible party
Eva Podbregar Kolar (MD, University Medical Centre Ljubljana) — Principal investigator
First posted
Aug 18, 2026
Start date
Apr 16, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Aug 18, 2026

Study contacts

Eva Podbregar Kolar, MD
Contact
evapodbregar@gmail.com
+38640762768

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Metformin

Start the discussion